Citadel Advisors
NERV icon

Citadel Advisors’s Minerva Neurosciences NERV Stock Holding History

Citadel Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,915
Closed -$22K – 14185
2025
Q1 		$22K Sell
12,915
-12,849
-50% -$25.4K ﹤0.01% 13075
2024
Q4 		$57.2K Buy
25,764
+8,525
+49% +$20.1K ﹤0.01% 12241
2024
Q3 		$46K Buy
+17,239
New +$50.1K ﹤0.01% 12007
2022
Q2 		– Sell
-1,842
Closed -$12K – 13684
2022
Q1 		$12K Sell
1,842
-4,504
-71% -$27.6K ﹤0.01% 13358
2021
Q4 		$41K Sell
6,346
-1,833
-22% -$17.3K ﹤0.01% 13357
2021
Q3 		$114K Sell
8,179
-3,211
-28% -$48.3K ﹤0.01% 12704
2021
Q2 		$211K Buy
11,390
+7,621
+202% +$164K ﹤0.01% 12042
2021
Q1 		$88K Buy
3,769
+1,184
+46% +$29.6K ﹤0.01% 12579
2020
Q4 		$48K Sell
2,585
-2,614
-50% -$65.8K ﹤0.01% 10578
2020
Q3 		$132K Sell
5,199
-2,239
-30% -$60.5K ﹤0.01% 9094
2020
Q2 		$215K Buy
7,438
+2,421
+48% +$142K ﹤0.01% 8422
2020
Q1 		$242K Buy
5,017
+1,487
+42% +$89.7K ﹤0.01% 7688
2019
Q4 		$201K Sell
3,530
-4,068
-54% -$179K ﹤0.01% 8181
2019
Q3 		$471K Sell
7,598
-1,747
-19% -$98.9K ﹤0.01% 6865
2019
Q2 		$420K Sell
9,345
-4,477
-32% -$224K ﹤0.01% 7076
2019
Q1 		$869K Buy
13,822
+2,242
+19% +$135K ﹤0.01% 5837
2018
Q4 		$625K Buy
11,580
+1,495
+15% +$109K ﹤0.01% 6060
2018
Q3 		$1.01M Buy
+10,085
New +$758K ﹤0.01% 5522
2017
Q3 		– Sell
-4,999
Closed -$354K – 7850
2017
Q2 		$354K Buy
4,999
+3,309
+196% +$214K ﹤0.01% 5632
2017
Q1 		$110K Buy
+1,690
New +$131K ﹤0.01% 6821

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's NERV Position: Q2 2025 in Review

Citadel Advisors sold out of Minerva Neurosciences (NERV) in Q2 2025, closing a stake of 12,915 shares — an estimated $22K sold.

Citadel Advisors first reported a position in NERV in Q1 2017 and held it in 20 quarters. The position peaked at $1.01M in Q3 2018. 21 funds tracked by Wall St. Rank hold NERV as of Q2 2025.

  • Citadel Advisors reported no remaining Minerva Neurosciences position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,915 Minerva Neurosciences shares in Q2 2025, an estimated $22K.
  • Citadel Advisors first reported a position in Minerva Neurosciences in Q1 2017 and held it in 20 quarters.
  • Citadel Advisors's Minerva Neurosciences position peaked at $1.01M in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.